Iterum Therapeutics plc

Hello and welcome everyone to the interim therapeutics third quarter 2025 financial results. My name is Becky and I will be your operator today. All lines will be muted throughout the presentation portion of the call with a chance for Q&A at the end. If you wish to ask a question in this time, please press start followed by one on your telephone keypads. I will now hand over to your host, Kevin Dalton, Senior Director of Legal Affairs to begin. Please go ahead.

Thank you, speaker. Good morning and welcome to Iterum Therapeutics' third quarter 2025 financial results. A press release with our third quarter results was issued earlier this morning and can be found on our website. We are joined this morning by our Chief Executive Officer, Corey Fishman, our Chief Financial Officer, Judy Mathews, and our Chief Commercial Officer, Christine Coyne. Corey and Christine will provide an update on the commercial launch of Orlimba in the US. Corey will also give an update on the business generally, and Judy will provide details on our financial results. We will then open the lines for Q&A. Before we begin, I would like to remind you that some of the information presented on this conference call will contain forward-looking statements concerning our plans, strategies, and prospects for our business. including our expectation that our Linva 2026 net product sales will be in a range between $5 and $15 million, the sufficiency of our cash resources to fund our operating expenses into Q2 2026, Our ability to continue the commercialization of Orlynda in the US. Our ability to expand into new territories and put additional resources in high prescribing geographies and to expand the payer coverage of Orlynda in the US. Our ability to raise funds either through a capital raise and or revenue generated from sales of Orlynda. the development, therapeutic, and market potential of our LINVA, and the protection provided by our patents. Actual results may differ materially from those indicated by these four end-of-life statements as a result of various factors outside our control. These include our ability to build and maintain a sales force and continue the commercialization of our LINVA in the US, the market opportunity for our potential market acceptance of our LINVA, the actions of third-party suppliers, manufacturers, and contract sales organizations, our ability to continue as a going concern, the accuracy of our expectations regarding how far into the future our cash on hand will fund our ongoing operations, and finally, other factors discussed under the caption risk factors in our annual report on Form 10Q filed with the SEC this morning. In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. We will also be referencing non-GAAP financial measures during the call. We have provided reconciliations of GAAP-reported to non-GAAP-adjusted information in the press release issued this morning. With that all said, I'll turn it over now to you, Corey, for your opening remarks.

Thank you, Kevin. Welcome to everyone, and thank you for joining us today. We're excited to be talking with you today and especially looking forward to sharing information about the early stages of the Orlinva commercialization. Just to remind you, we launched Orlinva into the market on August 20th of this year. Now I'd like to turn the call over to our Chief Commercial Officer, Christine Coyne.